Catholic Diocese of Richmond mourns passing of Pope Francis
RICHMOND (WAVY) – and the Catholic Diocese of Richmond are mourning the passing of Pope Francis.
Pope Francis, who suffered from chronic lung disease, passed away Monday morning at the age of 88. He made his last public appearance Easter Sunday, where he blessed thousands gathered in St. Peter's Square.
Complete Coverage: The Passing of Pope Francis
Bishop Knestout will offer Mass Monday at noon at the Cathedral of the Sacred Heart in Richmond. The diocese said all are welcome.
Bishop Knestout released the following statement after learning of the Pope's passing.
'Along with the faithful of the Catholic Diocese of Richmond, I mourn the passing of Pope Francis with great sadness and offer prayers to Our Lord for the happy repose of his soul.
As I reflect on his pontificate, I marvel at the way each Holy Father makes a unique imprint on the papacy and the Catholic Church. Pope Francis' charisms were his simple, conversational style, and his charitable efforts in reaching out to those on the peripheries – the poor, vulnerable, and alienated. His emphasis on synodality has taught us that by listening attentively to one another, we can love as Christ in a fractured and polarized world.
I was blessed to meet Pope Francis three times – most recently in Rome last October during a pilgrimage made by the parishioners of the Basilica of St. Andrew, Roanoke. During each of our encounters, the pope greeted me with a gentle, friendly smile, and just a few words in English: 'Pray for me!'
I assured him then of our prayers. We continue to pray now for this devoted shepherd of the Church. We commend his soul to the care of Christ, the Good Shepherd. Guided by Pope Francis' pastoral example, may the Church continually make progress in charity, imitating more perfectly Christ's merciful love in all we think, say, and do.'
Bishop Barry C. Knestout
In 2015, Pope Francis made a visit to the United States. WAVY News 10 traveled to DC for his trip there. Many from Hampton Roads will never forget the once-in-a-lifetime experience.
Links to video reports from WAVY's 2015 coverage of Pope Francis' visit to DC:
Pope Francis arrives in USVa. Beach family has close connection with Pope's latest Saint
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Medincell to Present 2024-2025 Annual Results on June 17, 2025
MONTPELLIER, France, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange. The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders: French session: 6:00pm CEST / 12:00pm ET> English session: 7:00pm CEST / 1:00pm ET> During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@ or asked live during the videoconferences. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. View source version on Contacts David Heuzé Head of Corporate and Financial Communications, and / +33 (0)6 83 25 21 86Grace Kim Chief Strategy Officer, U.S. / +1 (646) 991-4023Nicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@ / +33 (0)1 44 71 94 94Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@ / +33 (0)1 44 71 94 94 Sign in to access your portfolio
Business Wire
44 minutes ago
- Business Wire
Medincell to Present 2024-2025 Annual Results on June 17, 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange. The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders: French session: 6:00pm CEST / 12:00pm ET > English session: 7:00pm CEST / 1:00pm ET > During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@ or asked live during the videoconferences. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO ® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY ® (BEPO ® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", 'expect', "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", 'potential', "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.
Yahoo
a day ago
- Yahoo
Recall issued for potential significant risk with use of Zicam, Orajel swabs. What to know
A "potential microbial contamination" has lead to the recall of several cold nasal swabs and baby teething swabs, according to an announcement from the U.S. Food and Drug Administration June 9. All lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs have been recalled due to the potential contamination. The swabs can "potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections." Here's what you should know. Church & Dwight Co. is recalling all lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs due to potential microbial contamination identified as fungi in cotton swab components, according to a June 9 news release. The recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by the recall, the news released from the FDA said. As of June 9, "no serious adverse events" associated with the affected product have been reported, the FDA said. Recalled Zicam and Orajel swabs included in the recall are: Zicam Cold Remedy Nasal Swabs, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel Baby Teething Swabs, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. "Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. "The risk is highest — potentially severe or life-threatening — among children and individuals with compromised immune systems or other underlying medical conditions." The recalled products were distributed nationwide in the United States and in Puerto Rico. Consumers who have purchased any of the recalled products should stop using the product immediately, the FDA said. Go to or call the Consumer Relations team at 800-981-4710 for a full refund. This article originally appeared on Treasure Coast Newspapers: Zicam recall: cold nasal swabs. Also Orajel baby teething swabs
